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Introduction 
Solubility is one of the important parameters to achieve 
desired  concentration  of  drug  in  systemic  circulation 
for  achieving  required  pharmacological  response. 
Poorly water soluble drugs often require high doses in 
order to reach therapeutic plasma concentrations after 
oral  administration.  Low  aqueous  solubility  is  the 
major problem  with  formulation development  of  new 
chemical  entities.  Water  is  the  solvent  of  choice  for 
liquid pharmaceutical formulations. Most of the drugs 
are either weakly acidic or weakly basic having poor 
aqueous solubility. A great number of new and possibly 
beneficial  chemical  entities  do  not  have  suitable 
pharmaceutical  dosage  form  because  of  their  poor 
solubility and poor dissolution rate. The oral absorption 
of drugs is most often controlled by dissolution in the 
gastrointestinal tract.
1 
Rosuvastatin calcium is a BCS class II drug used as a 
lipid lowering agent by acting as HMG CoA reductase 
inhibitor.
2 Different methods are employed to improve 
the dissolution characteristics of poorly water soluble 
drugs  like  solubilization,  pH  adjustment,  cosolvents, 
microemulsion,  self  emulsification,  polymeric 
modification,  drug  complexation,  particle  size 
reduction, use of a surfactant as a solubilizing agent, 
the  pro-drug  approach  and  solid  solutions.
3 Amongst 
these,  the  most  promising  method  for  promoting 
dissolution is the use of the liquisolid system (LS).
4-13 
Liquisolid  systems  are  acceptably  flowing  and 
compressible  powdered  forms  of  liquid  medications. 
The term ‘liquid medication’ involves oily liquid drugs 
and solutions  or suspensions  of water  insoluble  solid 
drugs  carried  in  suitable  nonvolatile  solvent  systems 
termed  liquid  vehicles.  Employing  this  liquisolid 
technique, a liquid medication may be converted into a 
dry-looking,  non-adherent,  free  flowing  and  readily 
compressible powder by simple blending with selected 
powder  excipients  referred  to  as  carrier  and  coating 
materials.  
To  attain  the  flowability  and  compressibility  of 
liquisolid  compacts,  the  ‘‘mathematical  model  for 
liquisolid  systems”  was  employed  as  follows  to 
calculate  the  appropriate  quantities  of  excipients 
required  to  produce  liquisolid  systems  of  acceptable 
flowability  and  compressibility.  Various  grades  of 
cellulose,  starch  and  lactose  may  be  used  as  the 
carriers, whereas very fine particle size silica powders 
may be used as the coating (or covering) materials.
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Purpose: Rosuvastatin is a poorly water soluble drug and the rate of its oral absorption 
is  often  controlled  by  the  dissolution  rate  in  the  gastrointestinal  tract.  Hence  it  is 
necessary to increase the solubility of the Rosuvastatin.  
Methods: Several liquisolid tablets formulations containing various drug concentrations 
in liquid medication (ranging from 15% to 25% w/w) were prepared. The ratio of Avicel 
PH 102 (carrier) to Aerosil 200 (coating powder material) was kept 10, 20, 30. The 
prepared liquisolid systems were evaluated for their flow properties and possible drug-
excipient interactions by Infrared spectra (IR) analysis, differential scanning calorimetry 
(DSC) and X- ray powder diffraction (XRPD).  
Results:  The  liquisolid  system  showed  acceptable  flow  properties.  The  IR  and  DSC 
studies  demonstrated  that  there  is  no  significant  interaction  between  the  drug  and 
excipients.  The  XRPD  analysis  confirmed  formation  of  a  solid  solution  inside  the 
compact matrix. The tabletting properties of the liquisolid compacts were within the 
acceptable limits.  Liquisolid  compacts  demonstrated significantly  higher  drug  release 
rates than those of conventional and marketed tablet due to increasing wetting properties 
and surface area of the drug.  
Conclusion: This study shows that liquisolid technique is a promising alternative for 
improvement of the dissolution rate of water insoluble drug. 
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Due  to  low  solubility,  Rosuvastatin  shows  low 
bioavailability.  Various  approaches  to  enhance 
dissolution properties of Rosuvastatin are complexation 
with  β-cyclodextrin,  solid  dispersion,  hydrotropy, 
micellar solibilisation and microemulsion.
2,3 
Therefore,  the  present  work  is  aimed  towards 
enhancing  the  solubility,  dissolution  and  thereby  the 
bioavailability  of  Rosuvastatin  by  using  liquisolid 
compact technology.  
 
Materials and Methods 
Materials 
The following gift samples were received: Rosuvastatin 
(Biocon Pvt Ltd. Benglore, India); Avicel PH 102 and 
Sodium starch glycolate (Maple biotech Pvt. Ltd. Pune, 
India);  Aerosil  200(  Research  lab  Pune  India) 
propylene  glycol  (PG),  polyethylene  glycol  400 
(PEG400),  polyethylene  glycol  (PEG200)  and 
Acetonitrile (Research  lab,  Pune, India).  All  reagents 
used were of analytical grade. 
 
Saturation solubility studies 
Solubility studies of Rosuvastatin were carried out in 
distilled  water,  propylene  glycol,  PEG  400  and  PEG 
200.  Saturated  solutions  prepared  in  above  vehicles 
were kept in an orbital shaker (Remi motors Pvt. Ltd 
Mumbai, India.) for 72 h at 25 °C. The solutions were 
filtered and their concentration was determined by UV-
spectrophotometry  (Shimadzu  Corporation  Pvt.  Ltd. 
Nishinokyo-Kuwabara-cho,  Nakagyo-ku,  Kyoto  604-
8511, Japan ) at 241 nm. The results were determined 
as  the  percent  w/w  of  Rosuvastatin  in  its  saturated 
solution with the solvent under investigation. 
 
Application  of  a  mathematical  model  for  liquisolid 
system 
To  attain  the  flowability  and  compressibility  of 
liquisolid  compacts,  the  ‘‘new  formulation 
mathematical  model  of  liquisolid  systems”  was 
employed  as  follows  to  calculate  the  appropriate 
quantities of excipients required to produce liquisolid 
systems of acceptable flowability and compressibility. 
This  mathematical  model  was  based  on  new 
fundamental  powder  properties  (constants  for  each 
powder  material  with  the  liquid  vehicle)  called  the 
flowable  liquid  retention  potential  (Φ-value)  and 
compressible liquid retention potential (Ψ-number) of 
the constituent powders (carrier and coating materials) 
according to Spireas et al (Spireas. 2002; Spireas et al. 
1999). According to the new theories, the carrier and 
coating  powder  materials  can  retain  only  certain 
amounts  of  liquid  while  maintaining  acceptable  flow 
and  compression  properties.  Depending  on  the 
excipients ratio (R) or the carrier: coating ratio of the 
powder system used, where 
R =Q/q ... (1) 
As R represents the ratio between the weights of carrier 
(Q)  and  coating  (q)  materials  present  in  the 
formulation. An acceptably flowing and  compressible 
liquisolid system can be prepared only if a maximum 
liquid on the carrier material is not exceeded; such a 
characteristic amount of liquid is termed the liquid load 
factor  (Lf)  and  defined  as  the  ratio  of  the  weight  of 
liquid  medication  (W)  over  the  weight  of  the  carrier 
powder (Q) in the system, which should be possessed 
by an acceptably flowing and compressible  liquisolid 
system. i.e. 
Lf = W/Q ... (2) 
Spireas  et  al.  used  the  flowable  liquid  retention 
potentials (Φ -values) of powder excipients to calculate 
the  required  ingredient  quantities.  Hence  the  powder 
excipients  ratios  R  and  liquid  load  factors  Lf  of  the 
formulations are related as follows: 
Lf = Φ +Φ (1/R) ... (3) 
So,  in  order  to  calculate  the  required  weights  of  the 
excipients used, first, from equation (3), Φ and Φ are 
constants.  Therefore,  according  to  the  ratio  of  the 
carrier/ coat materials (R), Lf was calculated from the 
linear relationship of Lf versus 1/R. Next, according to 
the used liquid vehicle concentration, different weights 
of the  liquid  drug solution  (W)  will be  used.  So,  by 
knowing both Lf and W, the appropriate quantities of 
carrier (Q) and coating (q) powder materials required to 
convert a given amount of liquid medication (W) into 
an  acceptably  flowing  and  compressible  liquisolid 
system,  could  be  calculated  from  equations  (1)  and 
(2).
15 
 
Preparation  of  conventional  tablet  and  liquisolid 
compacts 
A conventional formulation of micronized Rosuvastatin 
calcium (denoted as DC) was directly compressed into 
cylindrical  tablets,  each  containing  5  mg  drug.  In 
addition,  each  DC  tablet  contained  the  following 
powder  excipients:  140  mg  Avicel  PH  102,  70  mg 
lactose monohydrate, 10 mg Aerosil 200, and 20 mg 
sodium starch glycolate. A 10 tablet batch was mixed 
in  a  mortar  for  10  min.  and  the  final  admixture  was 
compressed using a manual compression machine (Cip 
Machinaries.Pvt.  Ltd.  Ahrmadabad,  Gujarat).  Various 
liquisolid compacts containing 5 mg Rosuvastatin were 
prepared by dispersing in nonvolatile vehicles such as 
PEG 200. Then a binary mixture of carrier (Avicel PH 
102) and coating material (Aerosil-200) was prepared 
at a ratio of 20:1,10:1 and 30:1. This binary mixture 
was added to the admixture of drug and vehicle. From 
the calculated Φ-value, the liquid load factor (Lf) was 
calculated.
16 Depending upon the drug concentration in 
liquid  medication,  different  liquid  load  factors  were 
employed  in  liquisolid  preparations.  Different 
concentrations  of  Avicel  and  silica  were  used  to 
prepare  different  liquisolid  formulations.  Finally, 
sodium starch glycolate as a disintegrant was added to 
the above powder blend and mixed. The final powder 
blend was subjected to compression by using manual 
compression  machine  (Cip  Machinaries.  Pvt.  Ltd. 
Ahemadabad,  Gujarat.).  The  composition  of  the 
liquisolid compacts are shown in Table 1. 
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Table 1. Composition of the liquisolid compacts 
Drug in conc of 
PEG 200 
Batch  R value 
Drug 
(mg) 
Liquid load 
(Lf) 
Avicel PH 102 
(mg) 
Aerosil 
(mg) 
SSG 
(mg) 
PEG 200 
(mg) 
Unit dose 
(mg) 
15% 
F1  10  5  0.326  102.24  10.22  7.28  28.33  153.07 
F2  20  5  0.163  204  10.20  12.37  28.33  259.9 
F3  30  5  0.109  305.77  10.19  17.46  28.33  366.75 
20% 
F4  10  5  0.326  76.68  7.66  5.44  20  114.78 
F5  20  5  0.163  218.57  10.92  12.72  20  367.21 
F6  30  5  0.109  229.35  7.645  13.09  20  275.08 
25% 
F7  10  5  0.326  61.34  6.13  4.37  15  191.84 
F8  20  5  0.163  122.69  6.13  7.44  15  156.231 
F9  30  5  0.109  183.48  6.11  10.47  15  220.06 
 
Pre-compression studies of the liquisolid system 
Flow properties of the liquisolid system 
The  flow  properties  of  the  liquisolid  systems  were 
estimated  by  determining  the  angle  of  repose,  Carr’s 
index  and  Hausner’s  ratio.  The  angle  of  repose  was 
measured by the fixed funnel method. The bulk density 
and tap density were determined for the calculation of 
Hausner’s ratio and Carr’s index.
17 
 
Infra red spectra analysis 
IR spectrum of optimized formulation was recorded by 
KBr  method  using  Jasco  M4100  Fourier  Transform 
InfraRed spectrophotometer. A baseline correction was 
made by using dried potassium bromide and then the 
spectrum  of  powder  with  potassium  bromide  was 
recorded. Sample was scanned from 4000 to 400 cm
-1. 
The  compatibility  of  drug  and  other  excipients  in 
formulation  was  confirmed  by  comparing  drug  and 
formulation spectra. 
 
X-ray powder diffraction 
Crystallinity study was carried out by comparing XRD 
spectrum  of  drug  with  formulation  to  check  peak  of 
drug in individual state and in formulation. Study was 
carried  out  on  Elementer  Vario  E  L  III  XRD 
Sophisticated Analytical Instrument Facility, at Cochin. 
The data was recorded at 2θ range of 10 to 60 °C at 
time  of  0.5  sec.  the  relative  intensity  I/I0  and  inter- 
planar  distance  (d)  corresponding  to  2θ  value  were 
reported and compared. 
 
Differential scanning calorimetry (DSC) 
Thermograms  of  the  rosuvastatin  and  its  liquisolid 
formulations were recorded on Mettler STAR SW 9.01 
instruments. The analysis was carried out by heating 2 
to 3 mg of sample on an aluminum crimp pan at rate of 
10 °C/min in nitrogen atmosphere. 
 
In vitro evaluation of liquisolid compacts 
Content uniformity of rosuvastatin liquisolid tablets 
Ten  tablets  from  each  batch  were  taken  randomly  to 
examine  its  content  uniformity.  Each  tablet  was 
weighed and crushed individually. The crushed tablet 
powders  were  dissolved  in  acetonitrile  water  system. 
The  solution  was  filtered  using  Whatman  filter 
paper.The  drug  content  was  measured  using  UV 
spectrophotometer  (Shimadzu  corporation  Pvt.  Ltd 
Nishinokyo-Kuwabara-cho,  Nakagyo-ku,  Kyoto  604-
8511, Japan ) at 241 nm.  
 
Weight variation test 
Weight variation test was performed as per USP.
18 
 
Hardness and friability 
The  hardness  of  formulated  liquisolid  tablets  was 
assessed  using  a  Monsanto  hardness  tester  and  the 
mean  hardness  of  three  tablets  was  determined.  The 
friability  of  the  prepared  liquisolid  tablets  was 
measured  in  a  Roche  type  apparatus  (Electrolab  Pvt. 
Ltd Mumbai, India.) and the percentage loss in weight 
was calculated and used as a measure of friability.  
 
Disintegration test 
The  disintegration  test  was  carried  out  using 
disintegration test apparatus as specified in the Indian 
Pharmacopoeia. 
 
In vitro dissolution studies 
The  in-vitro  release  profiles  of  rosuvastatin  from 
liquisolid  compacts  and  directly  compressed  tablets 
were obtained using a dissolution test apparatus USP-II 
(Electrolab  Electrolab  Pvt.  Ltd  Mumbai,  India.)The 
dissolution study was carried out in 900 ml phosphate 
buffer pH 6.8 as the dissolution medium at 37 °C ± 2 
°C and 50 rpm. Then 5 ml samples were collected for 
up  to  60  min  at  5-min  intervals  .  The  dissolution 
medium was replaced with 5 ml fresh dissolution fluid 
to  maintain  sink  conditions.  The  withdrawn  samples 
were  filtered  and  analyzed  spectrophotometrically  at 
241 nm. The mean of three determinations was used to 
calculate  the  drug  release  from  each  of  the 
formulations.
18 
 
Estimation of fraction of molecularly dispersed drug  
The  fraction  (FM)  of  the  dissolved  or  molecularly 
dispersed drug in the liquid medication is the ratio the 
drug’s  saturation  solubility  (CL)  in  the  liquid  vehicle  
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over  the  drug  concentration  (Cd)  in  the  liquid 
medication. 
FM = CL / Cd (1) 
(Where FM = 1 when CL / Cd > 1) 
The fractions of the molecularly dispersed drug in any 
system cannot exceed unity. 
 
Effect of aging on tabletting properties 
The  study  was  performed  under  accelerated  stability 
conditions at 40 °C ± 2 °C/75% RH ± 5% RH for three 
months. 
 
Results and Discussion 
UV analysis and solubility study  
Rosuvastatin  in  acetonitrile-water  solution  obeyed 
Beer’s  law  and  displayed  linearity  over  the 
concentration  range  tested  from  2–20  μg/ml.  The 
solubility of the drug was studied in different solvents 
like  propylene  glycol,  polyethylene  glycol  200, 
polyethelene  glycol  400,  distilled  water,  Phosphate 
Buffer pH 6.8. Saturation solubility of rosuvastatin in 
various solvent is given in Table 2. 
 
Table 2. Saturated solubility of rosuvastatin in various solvent. 
Solvent  Solubility (%w/w) 
Distilled  water  0.00000043±0.037 
Buffer ph 6.8  0.0025±0.075 
PEG400  4.55±0.115 
Propylene glycol  9.96 ±0.180 
PEG200  11.57 ±0.205 
 
Selection of non volatile solvent  
Rosuvastatin has highest solubility in PEG 200. Since 
the aim of this study was to enhance the dissolution rate 
of drug, PEG 200 was chosen as the non volatile liquid 
vehicle  for  formulation  of  liquisolid  compacts  of 
Rosuvastatin. 
 
Application  of  a  mathematical  model  for  liquisolid 
system 
To  determine  the  quantities  of  the  ingredients  of  the 
compacts,, the flowable liquid-retention potentials (Φ-
values) and liquid load factor(Lf value) and the carrier 
to coating ratio (R value). 
Determination of flowable liquid-retention potential (Φ-
values)  
‘‘Angle of slide” measurement was used to evaluate the 
flow property of powder excipients (Avicel PH102 and 
Aerosil20  with  PEG200).  Several  uniform  liquid 
vehicle/powder  admixtures  which  contain  10  g  of  the 
carrier or coating materials with increasing amounts of 
liquid vehicle (PEG200) were prepared. To measure the 
angle  of  slide,  the  prepared  liquid/powder  admixtures 
were placed on polished metal plates, the plate was then 
tilted  gradually  until  the  liquid/powder  admixture  was 
about to slide. The angle formed between the plate and 
the horizontal surface was defined as the angle of slide 
(h). The flow properties of excipients will be change due 
to adsorption of the liquid vehicle. The flowable liquid-
retention  potential  (Φ  values)  of  each  liquid/powder 
admixture was calculated using the following equation. 
Φ value=weight of liquid/weight of solid 
The Φ -values for Avicel PH102 and Aerosil with PEG 
200 were 0.007 and 3.26 respectively. 
 
Determination of liquid load factor 
Using  the  Φ  –values  the  liquid  load  factor,  Lf,  was 
calculated according to equation 
Lf = Φ +Φ (1/R) 
The  Lf  values  were  used  to  calculate  the  required 
quantities of excipients. 
 
Pre-compression studies of the liquisolid system 
Flow properties of the Rosuvastatin liquisolid system 
The flow properties of the liquisolid powder system are 
influenced  by  physical,  mechanical  as  well  as 
environmental  factors.  Therefore,  different  flow 
parameters  were  employed  and  results  are  depicted  in 
Table 3. Batch F3 showed good flow properties with a θ 
value  of  30.02  and  was  considered  as  the  liquisolid 
system with acceptable flowability. Carr’s index up to 16 
was considered acceptable as a flow property. Hausner’s 
ratio was related to the inter particle friction; powders 
with  a  low  interparticle  friction  had  a  ratio  of 
approximately  1.25  indicating  a  good  flow.  Batch  F3 
with a Carr’s index of 12.10 and a Hausner’s ratio of 
1.17  was  considered  for  further  study  for  preparing 
batches of rosuvastatin liquisolid compacts. 
Table 3. Flow properties of rosuvastatin  liquisolid system 
Batch  Tap density (gm/cm3)  Bulk density (gm/cm3)  Angle Of  repose (θ)  Cars index  Hausner’s ratio 
F1  0.502±0.04  0.421±0.04  28.14±1.46  16.14±2.78  1.18±0.03 
F2  0.472±0.01  0.410±0.009  29.14±1.03  14.12±1.59  1.16±0.02 
F3  0.503±0.17  0.442±0.01  30.02±1.88  12.10±0.30  1.13±0.005 
F4  0.456±0.02  0.390±0.042  30.10±2.30  16.25±0.791  1.16±0.05 
F5  0.497±0.009  0.437±0.007  29.66±1.15  11.98±0.18  1.13±0.00 
F6  0.417±0.009  0.379±0.007  30.94±0.554  11.29±1.55  1.12±0.023 
F7  0.465±0.01  0.386±0.01  31.77±1.74  16.33±2.20  1.2±0.04 
F8  0.620±0.03  0.516±0.02  32.85±0.39  16.33±0.62  1.19±0.01 
F9  0.497±0.01  0.406±0.01  25.49±1.53  18.33±0.433  1.22±0.001 
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IR spectra analysis 
The  IR  spectrum  showing  percentage  transmission 
(T%) versus wave number of Rosuvastatin is shown in 
Figure  1  with  characteristic  peaks  of  aromatic  N-H 
stretching and C=O stretching at 3316 cm-1 and 1600 
cm-1, respectively. From the figure it was observed that 
functional  group  of  rosuvastatin  was  retained  in 
liquisolid  compact,  suggesting  absence  of  chemical 
interaction  with  any  of  the  excipients  used  in  the 
preparation of liquisolid compacts.
10 
 
 
Figure 1. FTIR spectra A) Liquisolid formulation, F3 B) 
Rosuvastatin C) Avicel D) Aerosil E) Sodium starch glycolate. 
 
X-ray powder diffraction (XRPD) 
Powder X-RD is used to determine the crystallinity of 
compounds.  Polymorphic  changes  of  drug  are 
important factor which might affect the dissolution rate 
and in turn bioavailability. Crystallinity of the drug and 
the liquisolid compacts samples was determined. The 
X-Ray  Diffraction  pattern  (Figure  2)  of  pure  drug 
(Rosuvastatin)  showed  sharp  diffraction  peaks  at  2θ 
values  of  16.04,  22.45,  and  34.3  while  liquisolid 
powder showed sharp peak at 2θ values of 19.87. The 
absence of characteristics peak in formulation indicated 
that  drug  had  probably  converted  from  crystalline  to 
amorphous form.
10 
 
Differential scanning calorimetry (DSC) 
The  possible  interactions  between  a  drug  entity  and 
excipients in liquisolid compacts were determined  by 
DSC. Figure 3 shows the thermal behavior of the pure 
components  as  well  as  of  the  final  liquisolid  system 
prepared.  The  rosuvastatin  peaks  appeared  clear, 
demonstrating a sharp characteristic endothermic peak 
at 125.38 °C (Figure 3A) corresponding to its melting 
temperature  (Tm);  such  a  sharp  endothermic  peak 
shows  that  the  rosuvastatin  used  was  in  a  pure 
crystalline  state.  On  the  other  hand,  the  liquisolid 
system (Figure 3B) showed that the characteristic peaks 
of  rosuvastatin  had  disappeared;  this  agrees  with  the 
formation of a solid solution in the liquisolid powdered 
system, i.e., the drug was molecularly dispersed within 
the  liquisolid  matrix.  That  was  accompanied  by  the 
formation  of  a  new  endothermic  peak  at  93.5.°C 
indicating  the  melting  and  decomposition  of  whole 
liquisolid  system.  This  disappearance  of  drug  peaks 
upon  formulation  into  a  liquisolid  system  was  in 
agreement  with  McCauley  and  Brittain  who  declared 
that  the  complete  suppression  of  all  drug  thermal 
features  undoubtedly  indicates  the  formation  of  an 
amorphous  solid  solution.  In  addition,  Mura  et  al. 
found that the total disappearance of the drug melting 
peak  indicates  that  drug  amorphization  had  taken 
place.
10 
 
 
Figure 2. X-ray diffractograms of A) Liquisolid powder system 
(F3) and B) Pure drug, Rosuvastatin. 
 
 
Figure 3. DSC thermogram of (A) Pure drug Rosuvastatin, (B) 
Liquisolid powder system (F3). 
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In vitro evaluation of liquisolid compacts 
Rosuvastatin liquisolid compact content uniformity 
A fundamental quality attribute for all pharmaceutical 
preparations is the requirement for a constant dose of 
drug  between  individual  tablets.  The  percent  drug 
content as shown in Table 4 varied from 90 to 97% w/w. 
 
Table 4. Post compression evaluation of Rosuvastatin liquisolid tablets 
Batch  Thickness 
(mm) 
Hardness 
(kg/cm
2) 
Weight variation 
(mg) 
Friability  Disintegration time 
(sec) 
Drug content 
(%) 
FM 
F1  3.02±0.01  4.20±0.24  151.45±0.95  0.095  175.00±0.63  96.66±1.31  0.771 
F2  3.53±0.01  4.08±0.25  256.51±0.95  0.126  210.00±0.89  92.83±1.32  0.771 
F3  3.45±0.01  4.00±0.15  363.64±0.85  0.274  143.33±0.81  96.66±1.31  0.771 
F4  2.06±0.01  3.33±0.51  110.96±1.10  0.089  253.5±1.37  92.85±1.28  0.578 
F5  3.42±0.01  4.00±0.44  363.62±0.91  0.072  307.0±0.89  96.66±1.31  0.578 
F6  3.63±0.00  3.66±0.51  272.27±0.95  0.099  226.83±1.16  90.58±1.36  0.578 
F7  3.00±0.02  3.5±0.44  187.25±1.19  0.094  354.66±0.81  90.58±1.36  0.462 
F8  2.84±0.00  3.58±0.58  151.8±0.92  0.199  182.83±0.75  92.11±1.28  0.462 
F9  2.65±0.01  4.00±0.31  216.20±0.44  0.168  254.66±1.03  95.13±1.32  0.462 
*All readings are average ± SD (n=3) 
 
Hardness, Friability, Weight variation, Disintegration 
test  
The results  of thickness,  hardness, weight  variation, 
friability,  disintegration  test  and  fraction  of 
molecularly dispersed drug (FM )of liquisolid tablet 
are  mentioned  in  Table  4.  All  the  selected 
Rosuvastatin tablets had acceptable friability as none 
of the  tested formulae  had  percentage loss  in  tablet 
weights  that  exceed  0.5%.  Also  none  of  the  tablets 
was  cracked,  split  or  broken.  The  liquisolid  tablet 
disintegrated in less than 5 minutes which is as per 
specifications given for the uncoated tablets in the IP. 
Uniform  drug  content  was  observed  for  all  the 
formulation (90 to 100). 
 
In vitro dissolution studies 
The drug dissolution profile of the liquisolid compact, 
the directly compressed compacts and marketed tablet 
of  rosuvastatin  at  different  dissolution  volume  and 
medium  was  studied.  Phosphate  buffer  pH  6.8,  900 
ml, was used as the dissolution medium. As seen in 
Figure 4, liquisolid compacts (F3) showed better  in-
vitro  release  than  those  of  the  directly  compressed 
tablet  and  marketed  tablet.  The  liquisolid  compacts 
contain  a  solution  of  the  drug  in  PEG  200  which 
facilitates the wetting of drug particle by decreasing 
the interfacial tension between tablet and dissolution 
medium. The drug surface available for dissolution is 
tremendously  increased.  After  disintegration,  the 
liquisolid  primary  particles  suspended  in  the 
dissolving medium contain the drug in a molecularly 
dispersed  state,  whereas  the  directly  compressed 
compacts  are  merely  exposed  micronized  drug 
particles.  Therefore,  in  the  case  of  liquisolid 
compacts,  the  surface  area  of  drug  available  for 
dissolution is much  greater than that  of the  directly 
compressed  compacts.  According  to  Noyes  and 
Whitney,  the  drug  dissolution  rate  (DR)  is  directly 
proportional to the concentration gradient (Cs-C) of 
the drug in the stagnant diffusion layer and its surface 
area  (S)  available  for  dissolution.  The  significantly 
increased  surface  area  of  the  molecularly  dispersed 
rosuvastatin  in  the  liquisolid  compacts  may  be 
principally  responsible  for  their  observed  higher 
dissolution  rates.  The  consistent  and  higher 
dissolution rate displayed by liquisolid compacts will 
improve the absorption of drug from the GI tract.  
 
 
Figure 4. Dissolution profile of liquisolid, marketed and directly 
compressed tablet. 
 
Effect of R Value on drug release from Rosuvastatin 
Liquisolid compacts: Spireas et al in their patent have 
stated that R value ranging from 10 to 30 gives optimal 
result.  In  the  present  study  different  drug 
concentrations in liquid medication were used between 
15-25%. Further for each drug to non volatile solvent R 
value was varied from 10 to 30 and its in vitro drug 
release  patterns  were  studied.  The  drug  release 
followed the following pattern: R30 > R20 > R10  
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Liquisolid  compacts  with  lower  R-values  contain 
relatively  smaller  amounts  of  carrier  powder  and 
larger quantities of fine drug loaded silica particles. 
Also,  the  ratios  of  the  amounts  of  their  liquid 
medication  per  powder  substrate  are  relatively 
higher. On the other hand, liquisolid compacts with 
higher  R-values  contain  low  liquid/powder  ratios, 
high presence of cellulose and low presence of silica. 
This  could  be  directly  associated  with  enhanced 
wicking,  disintegration  and  deaggregation 
properties. Therefore, the liquisolid tablets with low 
R-values showed relatively poor dissolution. 
Effect  of  different  drug  concentrations  in  liquid 
medication on drug release: PEG 200 was selected as 
nonvolatile vehicle as the drug rosuvastatin showed 
maximum solubility in it. Concentrations of drug in 
liquid medication were varied from 15 to 25%. The 
drug  release  when  compared  suggested  that  15% 
showed  highest  dissolution  profile  followed  by  20 
and there on . The drug release was high as higher 
fraction of drug was in solubilized or molecular state 
as compared to other concentrations. 
Thus, formulations with smaller drug concentration 
(15%w/w) have a higher dissolution than higher drug 
concentration  (25%w/w)  in  liquisolid  tablets 
formulated with PEG 200. This can be explained by 
the dissolved drug in the liquid medication. The drug 
release follows the following pattern: F3 > F6 > F9 
FM = Cl / Cd ---------------------- (4) 
Where FM is the fraction of molecularly dispersed or 
dissolved drug in liquid medication of the prepared 
liquisolid formulation, Cl is the saturation solubility 
of Rosuvastatin in the liquid vehicle and Cd is the 
concentration of the liquid. According to Spireas et 
al.  FM  value  cannot  exceed  unity.  The  saturation 
solubility  of  rosuvastatin  in  PEG  200  is  11.57  % 
w/w. By applying Equation 4, it was again seen that 
FM value is not greater than 1 .  
 
Effect of aging on tabletting properties 
The optimized formulation was subjected to stability 
studies  to  evaluate  any  change  in  the  formulation. 
Stability  study  of  optimized  formulation  was 
performed  under  accelerated  stability  conditions  at 
40 °C ± 2 °C/75% RH ± 5% RH for three months. 
The hardness, drug content and dissolution rate were 
measured  for  the  aged  tablets.  The  results  showed 
that  there  was  no  significant  different  between 
hardness of fresh (4Kg/Cm
2) and aged (4Kg/Cm
2) of 
the  liquisolid  tablets.  Figure  5.  too  shows  similar 
dissolution  profiles  between  the  fresh  and  aged 
formulation.  This  means  that  aging  had  no 
significant  effect  on  drug  release  profile  of 
rosuvastatin liquisolid tablets. The study concluded 
that the tested formulations are found to be stable. 
 
 
Figure 5. Disolution profile of F3 during Stability studies. 
 
Conclusion 
Rosuvastatin  exhibits  high  permeability  through 
biological  membranes,  but  its  absorption  after  oral 
administration is limited by its low dissolution rate due 
to its very low aqueous solubility. Hence, the use of the 
liquisolid  technique  was  chosen  to  enhance  the 
dissolution properties of rosuvastatin. The rosuvastatin 
liquisolid compacts were prepared using Avicel PH 102 
and  Aerosil  200  as  the  carrier  and  coating  material, 
respectively.  The  P-XRD  studies  showed  complete 
inhibition of crystallinity in the rosuvastatin liquisolid 
compacts.  The  DSC  study  confirmed  the  absence  of 
any interaction between the drug and excipients used in 
the  preparation  of  Rosuvastatin  liquisolid  compacts. 
The  hardness,  friability,  weight  variation  and 
disintegration tests were within acceptable limits. The 
in  vitro  dissolution  study  confirmed  enhanced  drug 
release  from  liquisolid  compacts  compared  with 
directly compressed tablet and marketed tablet. It was 
observed  that  aging  had  no  significant  effect  on  the 
hardness, disintegration time and dissolution profile of 
the liquisolid compacts. 
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